Modulation of Abeta Levels by GSK933776 in Alzheimer's Disease Patient

• The temporal changes of total and free amyloid beta levels in plasma after GSK933776 single dose administration in the patients with Alzheimer's disease and Mild Cognitive impairment [ Time Frame: Two months ] [ Designated as safety issue: No ]
• The temporal changes of Tau and phosphor Tau - 181 levels in CSF after GSK933776 single dose administration in the patients with Alzheimer's disease and Mild Cognitive impairment [ Time Frame: 22 hours ] [ Designated as safety issue: No ]
• Estimated pharmacokinetic parameters of AUC, Cmax and Tmax in CSF and plasma at multiple time points with various intervals. [ Time Frame: three months ] [ Designated as safety issue: No ]
• To assess the safety and tolerability after single dose of GSK933776 administration. [ Time Frame: three months ] [ Designated as safety issue: No ]
  The safety and tolerability measures are performed at screening, dosing day and follow up. The assessments included: • Adverse event reporting and safety laboratory data. • CNS Safety: MRI and MMSE. • CVS safety: ECG and vital signs. •Anti-GSK933776 antibodies.

• The temporal changes of total and free amyloid beta levels in plasma after GSK933776 single dose administration in the patients with Alzheimer's disease and Mild Cognitive impairment [ Time Frame: Two months ] [ Designated as safety issue: No ]
• The temporal changes of Tau and phosphor Tau - 181 levels in CSF after GSK933776 single dose administration in the patients with Alzheimer's disease and Mild Cognitive impairment [ Time Frame: 22 hours ] [ Designated as safety issue: No ]
• Estimated pharmacokinetic parameters of AUC, Cmax and Tmax in CSF and plasma at mutiple time points with various intervals. [ Time Frame: three months ] [ Designated as safety issue: No ]
• To assess the safety and tolerability after single dose of GSK933776 administration. [ Time Frame: three months ] [ Designated as safety issue: No ]
  The safety and tolerability measures are perfored at screening, dosing day and follow up. The assessments included: • Adverse event reporting and safety laboratory data. • CNS Safety: MRI and MMSE. • CVS safety: ECG and vital signs. •Anti-GSK933776 antibodies.

Modulation of beta-amyloid levels in CSF and plasma by GSK933776 in patients with mild Alzheimer's disease or mild cognitive impairment

This is a phase I, an open label, single dose and parallel group study to assess short term pharmacodynamics and safety of GSK933776. The effect on the beta amyloid levels will be assessed in early (MCI) and mild Alzheimer's disease (AD) patients after a single dose of GSK933776 by i.v. administration.

• Biological: GSK933776
  1mg/kg dose group
• Biological: GSK933776
  3mg/kg dose group
• Biological: GSK933776
  6mg/kg dose group

• Experimental: GSK933776 1mg/kg
  single dose
  Intervention: Biological: GSK933776
• Experimental: GSK933776 0.1 or 3mg/kg
  single dose
  Intervention: Biological: GSK933776
• Experimental: GSK933776 3 or 6mg/kg
  single dose
  Intervention: Biological: GSK933776

Inclusion Criteria:

• Probable mild Alzheimer's disease (MMSE 20-26) or mild cognitive impairment
• Increase in total tau or p-tau in CSF
• Decrease in amyloid beta in CSF
• Stable dose of cholinesterase inhibitors, memantine or selegine or no treatment
• Body weight less than 120 kg
• Willingness to comply with contraceptive methods if self or partner is of child-bearing potential

Exclusion Criteria:

• Any other cause of dementia
• Other significant neurologic or psychiatric illness
• Hachinski Ischemia Score >4
• More than 3 microbleeds on MRI
• Type 2 diabetes not controlled by diet
• Risk of cerebrovascular disease, cerebral haemorrhage or stroke
• History of systemic autoimmune disease
• Use of platelet anti-aggregates or anti-coagulants (Aspirin up to 325 mg/day is allowable)
• Use of chronic corticosteroids
• Uncontrolled hypertension in spite of antihypertensive medications
• Renal or hepatic insufficiency or clinically significant anaemia
• In nursing home care
• Contraindications to lumbar puncture or MRI
• Prior participation in therapeutic studies only after adequate wash-out period